Browse diseases

…d CD93 chimeric antigen receptor (CAR) T cells efficiently kill acute myeloid leukemia (AML) but risk endothelial cell (EC) toxicity due to CD93 expre…

…Background Challenges to developing immunotherapies for acute myeloid leukemia (AML) include the identification of suitable target antigens du…

…mited, largely due to the overlap of antigen expression between AML cells and normal hematopoietic cells. To identify novel, leukem…

…e production potential was assessed. Killing assays using human AML cell lines and healthy T cells were also performed. Statistical…

…althy donors (mean age 2.7) from PMID: 32415257. Most B-ALL and AML samples (107/114) were obtained at diagnosis. All samples were …

…Background Patients with acute myeloid leukemia (AML) are often older, which brings challenges of endurance and…

…hbehani GK, Riddell S, Cripe T, Cairo MS. Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vit…

… recently identified as a target of T-cell-directed therapy for acute myeloid leukemia (AML), based on the study reporting high BCMA abundance in AML …

…es NK cell activation and improves their therapeutic potential. AML, particularly in relapsed or refractory cases, remains a signif…

…Background Acute myeloid leukemia (AML) accounts for 25% of acute leukemias in children and 33% i…

…systems we currently employ. To address this issue we generated Acute Myeloid Leukemia (AML) and Ovarian Cancer (OC) models using three different mous…

…decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood. 2016. PMID: 26796361; PMCID: PMC4817311.Esposito CL, Au…